Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Direct-to-consumer health giants Noom and Hims & Hers are launching peptide therapy offerings, riding a wave of loosened federal restrictions on compounded treatments. Noom debuted a new brand called OpenRx, while Hims & Hers rolled out its Peptides+ specialty — both offering clinician-guided access to compounds like sermorelin and NAD+. Medical experts, including the AMA, are raising red flags over safety and the bypassing of FDA approval.
Direct-to-consumer health companies Noom and Hims & Hers are diving into the booming peptide market, capitalizing on a shift in federal enforcement policy that has opened the door for compounding pharmacies to produce previously restricted substances. Noom launched OpenRx, a new brand offering injectable peptides like sermorelin and NAD+, plus oral formulations targeting sexual health and intimacy. Hims & Hers unveiled its Peptides+ specialty, starting with five compounded treatments — Sermorelin, NAD+, Glutathione, Vitamin B12, and L-Carnitine — with more on the way.
The moves follow HHS Secretary RFK Jr.'s "enforcement discretion policy" issued in late October, which allows pharmacies and physicians to compound six popular wellness peptides without FDA approval. Both companies emphasize clinician oversight, U.S.-based compounding, and quality control — but the AMA has publicly pushed back, calling the policy "rushed" and warning that unproven peptides could expose patients to serious risks including allergic reactions, infections, and hormonal imbalances.
By the Numbers:
Why it matters: As peptide therapies go mainstream through DTC platforms, the tension between consumer demand, regulatory flexibility, and clinical evidence is coming to a head — with real implications for patient safety and the future of personalized medicine.